Migraine pill to widen treatment options for 170,000 sufferers
Atogepant has been given the green light for NHS use in England by the National Institute for Health and Care Excellence.
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
The NHS spending watchdog has recommended a once-daily pill to treat migraines on the health service in England for the first time in a move that will provide more treatment options for some 170,000 sufferers.
A migraine charity has called for “swift” access to the drug to ensure patients with the debilitating condition “can benefit from them as quickly as possible”.
Atogepant – sold under the brand name Aquipta and made by AbbVie – has been given the green light for NHS use under new final draft guidance from the National Institute for Health and Care Excellence (Nice).
It will be an option for people who have at least four migraine days a month, and who have tried at least three other treatments to no avail.
The pill works by blocking the receptor of a protein found in the sensory nerves of the head and neck, known as calcitonin gene-related peptide (CGRP).
CGRP makes blood vessels dilate, which can lead to inflammation and migraine.
The guidance is expected to give more choice to about 170,000 patients in England, Nice said.
Helen Knight, director of medicines evaluation at Nice, said: “Currently, the most effective options for people with chronic migraines who have already tried three preventative treatments are drugs that need to be injected.
“The committee heard from patient experts that some people cannot have injectable treatments, for example because they have an allergy or phobia of needles.”
Ms Knight said patients with chronic migraines – that happen on more than 15 days of the month – “would welcome an oral treatment”.
She added that Aquipta also “offers more choice” for people who suffer episodic migraines, which happen on fewer than 15 days of the month.
It is positive to see even more therapies emerging for people with migraine as many still rely on treatments developed for other conditions
According to The Migraine Trust, about 10 million adults in the UK are living with the condition.
The charity’s chief executive, Rob Music, said: “A migraine attack can be incredibly debilitating.
“Symptoms can include intense head pain, loss of or changes to the senses, and lack of ability to carry out day-to-day life.
“It is positive to see even more therapies emerging for people with migraine as many still rely on treatments developed for other conditions.
“We now need to ensure access is swift, so that migraine patients can benefit from them as quickly as possible.”
Health minister Andrew Stephenson said: “Migraines affect millions of people in this country and this new treatment will help prevent recurring migraine attacks when other medicines have failed.
“It will allow more people whose daily life is affected by this painful, debilitating condition to manage their migraines more effectively and to live their lives to the fullest.”
Nice’s guidance for England comes after Aquipta was recommended for use in Scotland by the Scottish Medicines Consortium (SMC) in October last year.
The recommendation from Nice means that suitable people living with migraine in England and Wales will have access to an additional treatment option that has the potential to improve their quality of life
Rachael Millward, medical director at AbbVie UK, said: “AbbVie has an extensive history in migraine research and is committed to addressing the unmet needs of people living with this debilitating condition.
“The recommendation from Nice means that suitable people living with migraine in England and Wales will have access to an additional treatment option that has the potential to improve their quality of life.”
Nice recommends that Aquipta should be stopped after 12 weeks if chronic migraines do not reduce by at least 30% and episodic migraine by at least 50%.
If there are no appeals against its final draft guidance, Nice is expected to publish its final guidance on the drug next month.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.